

SAFETY IN HUNTINGTON'S DISEASE CLINICAL TRIALS
Huntington Society of America Meeting, June 5, 2009
Phoenix, Arizona
JOHN N. CAVINESS, M.D.

Key Points:

- NEW TREATMENTS FOR HD MUST BE PROVED IN CLINICAL TRIALS TO BE **SAFE**
- BE ACTIVE, NOT PASSIVE, WHEN PARTICIPATING IN CLINICAL TRIALS
- EDUCATION AND COMMUNICATION ARE THE BEST TOOLS FOR SAFETY
- KNOW WHAT EFFECTS OF THE STUDY DRUG TO LOOK FOR
- NOTIFY STUDY COORDINATOR WITH **ANY POSSIBLE SIGNIFICANT MEDICAL EFFECT OF THE STUDY DRUG ON YOU, MILD OR SEVERE!!**
- There are multiple groups that provide safety oversight in a clinical treatment trial
 - Investigators, Study Sponsor/Funding group
 - Institutional Review Board, Data Safety Monitoring Board